Acquisition Enhances EMCORE's Presence in Telecommunications Market Segment

EMCORE Corporation, a leading provider of compound semiconductor-based components and subsystems for the broadband, fiber optic, satellite and terrestrial solar power markets, today announced completion of the acquisition of the telecom- related portion of Intel's Optical Platform Division. The telecom assets EMCORE acquired include intellectual property, assets and technology comprised of tunable lasers, tunable transponders, 300-pin transponders, and integrated tunable laser assemblies (ITLA). The acquisition agreement was signed and announced on December 18, 2007. The purchase price was $85 million in cash and common stock.

This acquisition enhances EMCORE's presence in the telecommunications market segment and expands its fiber optics product portfolio. The acquired assets will be integrated into EMCORE's Digital Products Division (EDP). "We are excited about the addition of the product portfolio, customer base, and the business and technical personnel from this acquisition. EMCORE is now one of a very few companies able to offer customers products for long-haul telecom, DWDM, enterprise and storage applications. Furthermore, EMCORE will leverage its infrastructure of contract manufacturing and the vertical integration on both the long- and short-wavelength products to continue its cost reduction effort," said Stephen Krasulick VP & GM of EDP. "We look forward to working closely with the customers of the Intel product lines and to further expanding and strengthening our relationship with our existing customer base," added Mr. Krasulick.

EMCORE will showcase its new fiber optic products, through its internal effort and from this Intel asset acquisition, at the upcoming Optical Fiber Communications (OFC) show in San Diego, California.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.